

## Supplementary Material

# Synthesis and *In Vitro* Antimycobacterial Activity of Novel N-Arylpiperazines Containing an Ethane-1,2-diyl Connecting Chain

Tomáš Goněc <sup>1</sup>, Ivan Malík <sup>2\*</sup>, Jozef Csöllei <sup>1</sup>, Josef Jampílek <sup>2</sup>, Jiřina Stolaříková <sup>3</sup>, Ivan Solovič <sup>4,5</sup>, Peter Mikuš <sup>6</sup>, Stanislava Keltošová <sup>7</sup>, Peter Kollár <sup>7</sup>, Jim O'Mahony <sup>8</sup> and Aidan Coffey <sup>8</sup>

<sup>1</sup> Department of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences in Brno, Palackého 1946/1, Brno CZ-612 42, Czech Republic; gonect@vfu.cz (T.G.), csollej@vfu.cz (J. Cs.)

<sup>2</sup> Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University in Bratislava, Odbojárov 10, Bratislava SK-832 32, Slovak Republic; malikivan001@gmail.com (I.M.); josef.jampilek@gmail.com (J.J.)

<sup>3</sup> Laboratory for Mycobacterial Diagnostics and Tuberculosis, Regional Institute of Public Health, Partyzánské náměstí 7, Ostrava CZ-702 00, Czech Republic; Jirina.Stolarikova@zu.cz (J.S.)

<sup>4</sup> Clinic for Tuberculosis and Lung Diseases, National Institute for Tuberculosis, Lung Diseases and Thoracic Surgery, Vyšné Hágy, Vysoké Tatry SK-059 84, Slovak Republic; solovic@hagy.sk (I.S.)

<sup>5</sup> Department of Public Health, Faculty of Health, Catholic University in Ružomberok, Hrabovecká cesta 1A, Ružomberok SK-034 01, Slovak Republic; ivan.solovic@ku.sk (I.S.)

<sup>6</sup> Department of Pharmaceutical Analysis and Nuclear Pharmacy, Faculty of Pharmacy, Comenius University in Bratislava, Odbojárov 10, Bratislava SK-832 32, Slovak Republic; mikus@fpharm.uniba.sk (P.M.)

<sup>7</sup> Department of Human Pharmacology and Toxicology, University of Veterinary and Pharmaceutical Sciences in Brno, Palackého 1946/1, Brno CZ-612 42, Czech Republic; kollarp@vfu.cz (P.K.); keltosovav@vfu.cz (S.K.)

<sup>8</sup> Department of Biological Sciences, Cork Institute of Technology, Bishopstown, Cork T12 P928, Ireland; jim.omahony@cit.ie (J.O.M.); aidan.coffey@cit.ie (A.C.)

\* Correspondence: malikivan001@gmail.com (I.M.); Tel.: +421-2-501-117-227

**Table S1.** Observed  $R_f$  values and calculated  $R_M$  parameters (RP-TLC) of the evaluated compounds **8a–h** using stationary phases (silica gel plates) impregnated with a variously concentrated silicone oil in heptane.

Entry	1%		3%		5%	
	$R_f$	$R_M$	$R_f$	$R_M$	$R_f$	$R_M$
<b>8a</b>	0.78	-0.55	0.59	-0.16	0.53	-0.05
<b>8b</b>	0.69	-0.35	0.52	-0.03	0.44	0.11
<b>8c</b>	0.59	-0.16	0.42	0.42	0.27	0.44
<b>8d</b>	0.49	0.01	0.27	0.27	0.19	0.64
<b>8e</b>	0.51	-0.02	0.39	0.19	0.36	0.25
<b>8f</b>	0.39	0.19	0.33	0.31	0.28	0.41
<b>8g</b>	0.29	0.39	0.21	0.58	0.22	0.55
<b>8h</b>	0.19	0.63	0.13	0.83	0.13	0.83

**Table S2.** Observed values of capacity factors  $k$  (RP-HPLC) of the investigated compounds **8a–h**, which were determined in the methanol (MeOH)/water mobile phases containing a varying volume ratio ( $v/v$ ) of the organic modifier.

Entry	$k$ ; MeOH/water ( $v/v$ )			
	$k$ ; 60:40	$k$ ; 70:30	$k$ ; 80:20	$k$ ; 85:15
<b>8a</b>	4.091	1.770	0.925	0.699
<b>8b</b>	4.951	2.778	1.245	0.879
<b>8c</b>	5.898	3.561	1.466	1.023
<b>8d</b>	6.738	5.039	1.769	1.185
<b>8e</b>	3.098	1.456	0.822	0.637
<b>8f</b>	4.524	2.053	1.023	0.757
<b>8g</b>	5.394	3.108	1.342	0.956
<b>8h</b>	7.598	4.627	1.736	1.173


**Table S3.** Relationships between the log  $k_w$  values and *in vitro* activity (in the log (1/MIC [M]) units) of the compounds under the study.

Equation No.	Strain (Days of Cultivation)/Series	Equation	Statistical Descriptors			
Eq. (S1)	<sup>1</sup> MT (14-d) / 8a-d	$\log(1/\text{MIC} [\text{M}]) = 2.4188$ $(\pm 0.0431) \times \log k_w - 2.2686$ $(\pm 0.1129)$	<sup>3</sup> RSS=0.0003,	<sup>4</sup> R=0.9997,	<sup>5</sup> Adj. R <sup>2</sup> =0.9991,	
			<sup>6</sup> RMSE=0.0119,	<sup>7</sup> NoR=0.0168,	<sup>8</sup> F=3143.04,	
			<sup>9</sup> Prob>F=0.0003 ***, <sup>10</sup> n=4			
Eq. (S2)	MT (14-d) / 8e-h	$\log(1/\text{MIC} [\text{M}]) = 1.4933$ $(\pm 0.1864) \times \log k_w + 0.7816$ $(\pm 0.4762)$	RSS=0.0235, R=0.9849, Adj. R <sup>2</sup> =0.9547, RMSE=0.1085, NoR=0.1534, F=64.20, Prob>F=0.0152 **, n=4			
Eq. (S3)	MT (21-d) / 8a-d	$\log(1/\text{MIC} [\text{M}]) = 2.4188$ $(\pm 0.0431) \times \log k_w - 2.2686$ $(\pm 0.1129)$	RSS=0.0003, R=0.9997, Adj. R <sup>2</sup> =0.9991, RMSE=0.0119, NoR=0.0168, F=3143.04, Prob>F=0.0003 ***, n=4			
Eq. (S4)	MT (21-d) / 8e-h	$\log(1/\text{MIC} [\text{M}]) = 1.5162$ $(\pm 0.4007) \times \log k_w + 0.6506$ $(\pm 1.0239)$	RSS=0.1088, R=0.9367, Adj. R <sup>2</sup> =0.8162, RMSE=0.2332, NoR=0.3298, F=14.32, Prob>F=0.0633, n=4			
Eq. (S5)	<sup>2</sup> MK (7-d) / 8a-d	$\log(1/\text{MIC} [\text{M}]) = 1.4282$ $(\pm 0.3673) \times \log k_w + 0.4700$ $(\pm 0.9610)$	RSS=0.0205, R=0.9398, Adj. R <sup>2</sup> =0.8248, RMSE=0.1011, NoR=0.1430, F=15.12, Prob>F=0.0602, n=4			

<sup>1</sup> MT, *Mycobacterium tuberculosis* My 331/88 (*M. tuberculosis* H37Rv); <sup>2</sup> MT, *Mycobacterium kansasii* My 235/80;

<sup>3</sup> RSS, residual sum of squares; <sup>4</sup> R, correlation coefficient; <sup>5</sup> Adj. R<sup>2</sup>, adjusted coefficient of determination;

<sup>6</sup> RMSE, root mean squared error (standard deviation); <sup>7</sup> NoR, norm of residuals; <sup>8</sup> F, Fisher's significance ratio (Fisher's F-test); <sup>9</sup> Prob>F, probability of obtaining the F Ratio (significance of a whole model); <sup>10</sup> n, number of cases (points). The indication of a significance level of the F Ratio: \* (one star), statistically significant; \*\* (two stars), statistically very significant; \*\*\* (three stars), statistically extremely significant. The insignificant relationships were indicated by a red colour.



**Figure S1.** Survival rate curves of the compounds 8a-h in a THP-1 cell line after the 24 h treatment.